What is the 13F Pro Quality Score for TNYA?

13F Pro ranks Tenaya Therapeutics, Inc. (TNYA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TNYA's current score at https://13fpro.ai/research/TNYA (free sign-up required for the full ranking).

Where does 13F Pro source TNYA data?

All Tenaya Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Tenaya Therapeutics, Inc. files with the SEC under CIK 1858848. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TNYA in?

Tenaya Therapeutics, Inc. (TNYA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TNYA research updated on 13F Pro?

TNYA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Tenaya Therapeutics, Inc.(TNYA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1858848 TNYA stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

TNYA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Tenaya Therapeutics, Inc. (TNYA), a Healthcare sector company. TNYA is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Tenaya Therapeutics, Inc. reports quarterly revenue of $225.0K, net income of $-19.3M, free cash flow of $-19.2M. Top institutional holders of TNYA by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, MILLENNIUM MANAGEMENT, Empery Asset Management,, based on the most recent SEC filings. TNYA trades on the Nasdaq exchange and files with the SEC under CIK 1858848. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TNYA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Tenaya Therapeutics, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$225.0K

Net Income

Q1 2026

$-19.3M

Free Cash Flow

Q1 2026

$-19.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+18.5% YoY

$-90.6MFY 2025

FY22 $-123.7MFY23 $-124.1MFY24 $-111.1MFY25 $-90.6M

Operating Income

+19.5% YoY

$-93.3MFY 2025

FY22 $-125.6MFY23 $-131.2MFY24 $-115.9MFY25 $-93.3M

EPS (Diluted)

+55.0% YoY

$-0.59FY 2025

FY22 $-2.76FY23 $-1.68FY24 $-1.31FY25 $-0.59

Total Assets

+22.5% YoY

$146.9MFY 2025

FY22 $278.9MFY23 $170.5MFY24 $119.9MFY25 $146.9M

Op. Cash Flow

+24.6% YoY

$-68.3MFY 2025

FY22 $-104.4MFY23 $-102.1MFY24 $-90.5MFY25 $-68.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Income	$-90.6M +18.5%	$-111.1M +10.4%	$-124.1M -0.3%	$-123.7M -70.1%	$-72.7M -89.4%	$-38.4M
Operating Income	$-93.3M +19.5%	$-115.9M +11.6%	$-131.2M -4.4%	$-125.6M -72.5%	$-72.8M -87.1%	$-38.9M
EPS (Diluted)	$-0.59 +55.0%	$-1.31 +22.0%	$-1.68 +39.1%	$-2.76 +32.7%	$-4.10	—
Total Assets	$146.9M +22.5%	$119.9M -29.7%	$170.5M -38.9%	$278.9M -11.2%	$314.2M +112.1%	$148.2M
Operating Cash Flow	$-68.3M +24.6%	$-90.5M +11.3%	$-102.1M +2.3%	$-104.4M -71.7%	$-60.8M -71.6%	$-35.4M

AI Insight: TNYA Financial Trends

Tenaya's quarterly losses narrowed from -$29M in Q2 2024 to -$19M in Q1 2026 while cash burn improved.

• Net income losses decreased from -$29M in Q2 2024 to -$19M in Q1 2026, a 34% improvement.

• Operating cash flow burn improved from -$24M in Q2 2024 to -$19M in Q1 2026.

• Equity declined from $134M in Q2 2024 to $106M in Q1 2026 as company burns cash.

⚠ Equity rose to $123M in Q4 2025 before falling to $106M in Q1 2026, suggesting potential dilutive funding.

⚠ Still no revenue generation after eight quarters of reported losses limits operational leverage potential.

AI Insight: TNYA Ratio Trends

Tenaya's returns improved meaningfully in Q4 2025 before deteriorating again, with ROE recovering from -97.9% to -65.5% then declining to -72.6%.

• ROE improved sharply from -97.9% in Q3 2025 to -65.5% in Q4 2025, marking the best quarterly performance in the dataset.

• ROA followed similar pattern, recovering from -77.2% in Q3 2025 to -54.9% in Q4 2025 before weakening to -57.1%.

• ROIC remains highly volatile and deeply negative, ranging from -67.4% to -96.5% across measured quarters.

⚠ Latest quarter ROE deteriorated to -72.6% from -65.5%, reversing the Q4 2025 improvement and signaling continued operating challenges.

⚠ Missing ROIC data in Q3 2024 and Q3 2025 creates gaps in trend analysis during key periods.

Get alerted when TNYA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Tenaya Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TNYA

VANGUARD CAPITAL MANAGEMENT LLC
$5.9M8,482,288 sh
MILLENNIUM MANAGEMENT LLC
$3.8M5,456,666 sh
Empery Asset Management, LP
$3.0M4,286,933 sh
CITADEL ADVISORS LLC
$2.9M4,200,000 sh
RENAISSANCE TECHNOLOGIES LLC
$2.6M3,713,761 sh
BlackRock, Inc.
$2.6M3,703,955 sh
MARSHALL WACE, LLP
$1.9M2,705,390 sh
Burkehill Global Management, LP
$1.4M2,000,000 sh
Kalehua Capital Management LLC
$1.4M2,000,000 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.1M1,559,939 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$5.9M	8,482,288
MILLENNIUM MANAGEMENT LLC	$3.8M	5,456,666
Empery Asset Management, LP	$3.0M	4,286,933
CITADEL ADVISORS LLC	$2.9M	4,200,000
RENAISSANCE TECHNOLOGIES LLC	$2.6M	3,713,761
BlackRock, Inc.	$2.6M	3,703,955
MARSHALL WACE, LLP	$1.9M	2,705,390
Burkehill Global Management, LP	$1.4M	2,000,000
Kalehua Capital Management LLC	$1.4M	2,000,000
GEODE CAPITAL MANAGEMENT, LLC	$1.1M	1,559,939

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TNYA on your watchlist

Track score changes the day Tenaya Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TNYA a good stock to buy?

13F Pro's AI-powered analysis of Tenaya Therapeutics, Inc. (TNYA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TNYA are available on the TNYA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TNYA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TNYA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Tenaya Therapeutics, Inc.'s investment landscape.